Geographic Atrophy: Expanding Our Understanding of the Disease and its Management LIVE
Overview
Geographic atrophy (GA) is an advanced form of age-related macular degeneration for which there is currently no treatment approved by the US FDA. This webinar will review in-depth the latest information on GA, including the investigative therapies showing positive outcomes in clinical trials. The expert faculty will also share their expertise related to the optimal imaging modalities for evaluating GA and share case studies for discussion.Grantor Statement: Supported from an Educational Grant from Apellis. Learning Objectives
- Describe the prevalence of AMD and classify by severity: early, intermediate, and advanced (ie, wet AMD and GA)
- Explain the pathogenesis of GA
- Distinguish which imaging modalities are best suited for GA evaluation
- Categorize new therapies in the pipeline for GA
- Evaluate the functional and anatomic outcomes used in managing patients with GA
Accreditation
Provided by Evolve Medical Education
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
DISCLOSURE POLICY
Faculty:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Rishi P. Singh, MD Staff Physician Cole Eye Institute Associate Professor of Ophthalmology Cleveland Clinic Lerner College of Medicine Cleveland, Ohio
Nathan Steinle, MD
California Retina Consultants
Santa Barbara, CA
Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Houston Methodist Hospital
Blanton Eye Institute
Houston, Texas
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:Rishi P. Singh, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Bausch + Lomb, Genentech, Novartis, and Regeneron Pharmaceuticals. Grant/Research Support: Apellis and Graybug.
Nathan Steinle, MD, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech, Novartis and Regeneron Pharmaceuticals; Grant Research Support: Genentech, Novartis and Regeneron Pharmaceuticals; Speaker: Genentech, Novartis and Regeneron Pharmaceuticals.
Charles C. Wykoff, MD, PhD, FACS, and/or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera, Allergan, Genentech, Novartis, and Regeneron. Grant/Research Support: Allergan, Genentech, Novartis, and Regeneron. Speaker’s Bureau: Regeneron.
The Evolve staff and planners have no financial relationships with commercial interests.
Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal


























